강형진 (서울대학교 의과대학, 서울대학교병원)님 | 한빛사연구자 > 한빛사

서울대학교 의과대학, 서울대학교병원

최종업데이트 2025.08.07.

[LETTER] Prospective phase II study of allogeneic hematopoietic stem cell transplantation with targeted busulfan, fludarabine, and etoposide conditioning in pediatric acute lymphoblastic leukemia
- Hemasphere, Dec 2024, 8 (12) e70051 | https://doi.org/10.1002/hem3.70051
- 2024-12
- 의약학
- 한빛사논문
Comparable outcomes for pediatric acute lymphoblastic leukemia patients receiving conditioning with total body irradiation or chemotherapy: A nationwide, Korean registry-based study
- Hemasphere, Jun 2025, 9 (6) e70158 | https://doi.org/10.1002/hem3.70158
- 2025-06
- 의약학
- 한빛사논문
Somatic uniparental disomy mitigates the most damaging EFL1 allele combination in Shwachman-Diamond syndrome
- Blood, 2021 Jun 11;blood.2021010913 | https://doi.org/10.1182/blood.2021010913
- 2021-06
- 의약학
- 한빛사논문
- 강형진(서울대학교 의과대학)
Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in children: a randomised, double-blind, phase 3 trial
- Lancet Oncol., Volume 16, Issue 4, April 2015, Pages 385–394, DOI: http://dx.doi.org/10.1016/S1470-2045(15)70061-6
- 2015-04
- 의약학
- 한빛사논문
FK506 causes cellular and functional defects in human natural killer cells
- J. Leukoc. Biol., 2010 Dec; 88(6):1089-97 | doi: 10.1189/jlb.0310148
- 2010-12
- 의약학
- 구.추천논문

연구자 ID

저자논문